Meeting
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
Authors
Alicia K. Morgans
Dana-Farber Cancer Institute, Boston, MA
Alicia K. Morgans , Neal D. Shore , Nasreen Khan , Niculae Constantinovici , Javeed Khan , Guifang Chen , Julie Xu , Jorge A. Ortiz , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Other Prostate, Testicular, or Penile Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5097)
DOI
10.1200/JCO.2023.41.16_suppl.5097
Abstract #
5097
Poster Bd #
191
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
First Author: Daniel J. George
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database.
First Author: Benjamin H Lowentritt
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2021 ASCO Annual Meeting
Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.
First Author: Karim Fizazi